Healthcare Providers and Services
Company Overview of GeneOhm Sciences Canada Inc.
GeneOhm Sciences Canada Inc. provides genomic and molecular diagnostic services. The company is based in Quebec, Canada. GeneOhm Sciences Canada Inc. operates as a subsidiary of Becton, Dickinson and Company.
2555 boulevard du Parc-Technologique
Quebec, QC G1P 4S5
Key Executives for GeneOhm Sciences Canada Inc.
Worldwide Director of Scientific Affairs for Diagnostic Systems
Director of North American Scientific Affairs - Diagnostic Systems
Compensation as of Fiscal Year 2015.
GeneOhm Sciences Canada Inc. Key Developments
BD Diagnostics Reports Unaudited Revenue Results for the Fourth Quarter and Year Ended September 30, 2014
Nov 4 14
BD Diagnostics reported unaudited revenue results for the fourth quarter and year ended September 30, 2014. For the quarter, the company reported total revenues of USD 708 million against USD 680 million a year ago. The growth was driven by solid sales in the Preanalytical Systems and Diagnostic Systems units.
For the nine months, the company reported total revenues of USD 2,713 million against USD 2,646 million a year ago.
BD Diagnostics Expands its Suite of Open System Solutions on the Fully Automated BD MAX(TM) Platform
Aug 4 14
BD Diagnostics announced the availability of the Total Nucleic Acid (TNA) suite of reagents for the BD MAX System. The BD MAX System is the first molecular system which allows laboratories developing tests to combine extraction, amplification, and detection on a single, easy-to-use, automated platform. With this expansion of the Open System Reagent suite to accommodate TNA, laboratories and test developers using the BD MAX System can now realize the benefits of this fully automated platform for assays which incorporate DNA and RNA targets. These new reagents complement the current suite of BD MAX Open System Reagents by enabling the development of assays which use a single unitized strip, consolidating reagents for extraction and amplification of DNA and RNA. The BD MAX System shifts the traditional paradigm for user-developed molecular assays from a labor-intensive process requiring multiple instruments to streamlined, integrated format.
BD Diagnostics Receives FDA 510k Clearance for the BD ProbeTec Chlamydia Trachomatis
Jul 28 14
BD Diagnostics announced it has received 510(k) clearance from the U.S. Food and Drug Administration for the BD ProbeTec(TM) Chlamydia trachomatis (CT) Q(x) Amplified DNA Assay and the BD ProbeTec(TM) Neisseria gonorrhoeae (GC) Q(x) Amplified DNA Assay on the BD Viper(TM) LT System. The BD Viper LT System is a bench-top molecular platform that automates sample liquid handling, nucleic acid extraction, amplification, detection and result reporting without any user intervention. The BD Viper LT System is designed to manage primary sample tubes with pierceable caps and ready to use reagents. This "load and go" reagent and sample capability along with the easy to use design of the BD Viper LT System delivers true walkaway time to the laboratorian and maximizes productivity. The combination of the BD Viper LT System and the BD ProbeTec Chlamydia trachomatis (CT) Q(x) and the BD ProbeTec Neisseria gonorrhoeae (GC) Q(x) Amplified DNA Assays brings an innovative solution to microbiology and molecular labs that increases flexibility and improves laboratory efficiency. Improved efficiency provides more timely diagnostic information to clinicians for more effective patient management of two of the most common sexually transmitted bacterial infections - Chlamydia and gonorrhea. If left untreated, these infections can lead to pelvic inflammatory disease, infertility, ectopic pregnancy and chronic pelvic pain.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries